Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC Vaccine and Checkpoint Blockade for Relapsed Pediatric High-Grade Glioma
NCT03879512Phase 2Completed
- Start
- Feb 2018
- Primary completion
- Jul 2024
- Countries
- 1
01
Overview
Phase 2, open-label trial in glioma. Primary endpoint: 6 month Overall Survival. Started Feb 2018; status: completed.
02
Conditions
glioma
Beyond the preview
Go deeper on NCT03879512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03879512.